October 17, 2022: We are concerned screening for asymptomatic depression and suicide has more risks than benefits. Further research is needed to find methods that accurately identify at-risk patients.
Read More »On Health Policy
Patient, Consumer, and Public Health Coalition Letter to Senate HELP and Energy and Commerce Committee Regarding User Fee Reauthorization Legislation
September 22, 2022: It is critically important that House and Senate committees work together to consolidate differences between the Food and Drug Amendments Act (H.R. 7667), which passed the House of Representatives on June 8, and the Food and Drug Administration Safety and Landmark Advancements Act (S. 4348), which passed the Senate Health, Education, Labor, and Pensions (HELP) Committee on June 15.
Read More »Comment of the National Center for Health Research Submitted to the EPA on the Designation of PFOA and PFOS as CERCLA Hazardous Substances, October 6, 2022
October 6, 2022: In our public comment to the EPA, the National Center for Health Research agrees with EPA’s proposed designation of PFOA and PFOS as CERCLA hazardous substances. Holding companies accountable for these toxic chemicals, and other PFAS chemicals, will improve human health.
Read More »Testimony of Diana Zuckerman at the Meeting of EPA’s National Environmental Justice Advisory Council on September 28, 2022
September 28, 2022: I want to comment very briefly on the PFAS recommendations, since that’s an issue we’ve worked on for years. Let me add that we are very concerned about all endocrine disrupting chemicals not just PFAS.
Read More »NCHR Letter to Sen. Smith in Support of Women’s Health Legislation
September 22, 2022: Two bills led by Sen. Smith take critical steps to help protect access to safe and effective reproductive health care products. We at NCHR are appreciative of her work to act in the face of the many challenges presented following the Dobbs decision.
Read More »